作者
Juan Fortea, María Carmona-Iragui, Bessy Benejam, Susana Fernández, Laura Videla, Isabel Barroeta, Daniel Alcolea, Jordi Pegueroles, Laia Muñoz, Olivia Belbin, Mony J de Leon, Aleksandra Maleska Maceski, Christophe Hirtz, Jordi Clarimón, Sebastián Videla, Constance Delaby, Sylvain Lehmann, Rafael Blesa, Alberto Lleó
发表日期
2018/10/1
期刊
The Lancet Neurology
卷号
17
期号
10
页码范围
860-869
出版商
Elsevier
简介
Background
Diagnosis of Alzheimer's disease in Down syndrome is challenging because of the absence of validated diagnostic biomarkers. We investigated the diagnostic performance of plasma and CSF biomarkers in this population.
Methods
We did a cross-sectional study of adults aged 18 years and older with Down syndrome enrolled in a population-based health plan in Catalonia, Spain. Every person with Down syndrome assessed in the health plan was eligible to enter the Down Alzheimer Barcelona Neuroimaging Initiative, and those with a plasma or CSF sample available were included in this study. Participants underwent neurological and neuropsychological examination and blood sampling, and a subset underwent a lumbar puncture. Adults with Down syndrome were classified into asymptomatic, prodromal Alzheimer's disease, or Alzheimer's disease dementia groups by investigators masked to …
学术搜索中的文章
J Fortea, M Carmona-Iragui, B Benejam, S Fernández… - The Lancet Neurology, 2018